Endocrine News Podcast

The Endocrine Society recently released a new Clinical Practice Guideline (CPG) on Central Precocious Puberty. Among its many recommendations, the CPG says some subgroups of children with precocious puberty—such as older girls with slowly progressing puberty—may not need the same level of testing or treatment.
Central precocious puberty happens when a child’s brain activates puberty-related hormones too early—before age 8 years in girls and before age 9 years in boys. This early hormone signaling triggers physical changes such as breast development in girls, testicular enlargement in boys, rapid growth, and, in some cases, early menstruation.
Host Aaron Lohr talks with authors of the CPG on Central Precocious Puberty: Ana Latronico, MD, PhD, Professor of Endocrinology and Metabolism at Sao Paolo University and Stephanie Roberts, MD, pediatric endocrinologist and Assistant Professor of Pediatrics at Boston Children's Hospital.

The U.S. Food and Drug Administration recently qualified "total hip bone mineral density" as a surrogate endpoint to support clinical trials for osteoporosis drugs. This decision will significantly impact clinical trials moving forward, as the traditional endpoint of "fracture outcomes" presented many challenges regarding sample size, duration, and cost.
The change came about because of findings from the study to advance bone mineral density as a Regulatory Endpoint Project, also known as the SABRE project.
What is the SABRE project, and how did it arrive at these findings? How will this decision affect the design of clinical trials and time to approval of new osteoporosis therapies?
To help answer these questions and many more, Host Aaron Lohr spoke with three leaders of the SABRE Project: Dennis M. Black, PhD, professor of epidemiology and biostatistics at the University of California, San Francisco; Richard Eastell, MBChB, PhD, FRCP, FMedSci, professor of bone metabolism at the University of Sheffield, and Mary L. Bouxsein, PhD, professor of orthopedic surgery at Harvard Medical School.

The endocrine workforce shortage is affecting the lives of endocrinologists and the patients they treat. Many practices would benefit from any support that would give endocrinologists more capacity to focus where they really need to. Could advance practice providers, such as nurse practitioners and physicians assistants, be able to provide that support if they had a little more training?   The Endocrine Society and the American Association of Nurse Practitioners? (AANP) think so. Together they have developed a new program called Clinical Advantage: Endocrinology Certificate for Advanced Practice Providers. What does the certificate represent, how does the program work?   To help answer those questions and more host Aaron Lohr talks with two guests who helped develop the program: Sara R. MacLeod, DO, MPH, Assistant Professor of Medicine at University of Rochester; and Shannon K. Idzik, DNP, CRNP, ANP-BC, FAANP, FAAN, Professor and Associate Dean for the Doctor of Nursing Practice Program at University of Maryland School of Nursing.   Listen to learn how Clinical Advantage is working to address the shortage. Show notes are available at